Capricor Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Capricor Therapeutics (NASDAQ: CAPR) announced participation in two investor events in Miami on Wednesday, June 10: the Goldman Sachs 47th Annual Global Healthcare Conference, featuring a fireside chat and investor meetings at 10:00 a.m. ET, and the Oppenheimer CNS and Neuro-Muscular Summit.

A live webcast and replay of the Goldman Sachs session will be accessible via the Investors section of Capricor’s website. The company is developing Deramiocel for Duchenne muscular dystrophy and advancing its StealthX exosome platform.

News Market Reaction – CAPR

-2.06%

-2.06% Session close to close

In the Jun 8 session, CAPR declined 2.06%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.  

• Goldman Sachs 47^th Annual Global Healthcare Conference, Miami, FL
  • Fireside chat and investor meetings: Wednesday, June 10, at 10:00 a.m. ET
  • Webcast: Click here
• Oppenheimer CNS and Neuro-Muscular Summit, Miami, FL
  • Industry panel and investor meetings: Wednesday, June 10
    

A replay of the Goldman Sachs webcast will be available after the conclusion of the live event and will be accessible in the Investors section of the Company’s website.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (DMD), shown in clinical studies to preserve cardiac and skeletal muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval, revenue and reimbursement estimates, projected terms of definitive agreements, our financial position, our possible uses of existing cash and investment resources, and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as filed with the Securities and Exchange Commission on May 13, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Deramiocel and the StealthX™ vaccine are investigational candidates and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:
Caitlin Kasunich
KCSA Strategic Communications
ckasunich@kcsa.com
212.896.1241

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

FAQ

When will Capricor Therapeutics (NASDAQ: CAPR) present at the Goldman Sachs 47th Annual Global Healthcare Conference?

Capricor Therapeutics will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, June 10, at 10:00 a.m. ET. According to Capricor, the session will include a fireside chat and investor meetings in Miami, Florida.

How can investors access the Capricor (CAPR) Goldman Sachs healthcare conference webcast and replay?

Investors can access Capricor’s Goldman Sachs conference fireside chat via a live webcast, with a replay available afterward. According to Capricor, both will be hosted in the Investors section of the company’s website for convenient on-demand viewing.

What is Capricor Therapeutics (CAPR) doing at the Oppenheimer CNS and Neuro-Muscular Summit on June 10, 2026?

Capricor will participate in an industry panel and hold investor meetings at the Oppenheimer CNS and Neuro-Muscular Summit on Wednesday, June 10. According to Capricor, the event takes place in Miami and focuses on central nervous system and neuromuscular topics.

What does Capricor Therapeutics (CAPR) develop, including Deramiocel and the StealthX platform?

Capricor develops cell and exosome-based therapeutics for rare diseases, including its lead candidate Deramiocel. According to Capricor, Deramiocel is in late-stage development for Duchenne muscular dystrophy, and the proprietary StealthX exosome platform targets delivery of diverse therapeutic payloads.

Is Capricor’s Deramiocel approved for commercial use in Duchenne muscular dystrophy?

Deramiocel is not approved for commercial use in any indication. According to Capricor, Deramiocel and the StealthX vaccine are investigational candidates, despite clinical data showing preservation of cardiac and skeletal muscle function in Duchenne muscular dystrophy studies.

Where can investors find more information about Capricor Therapeutics (NASDAQ: CAPR) and its upcoming events?

Investors can learn more about Capricor and its events on the company’s website, including the Investors section. According to Capricor, details on webcasts, replays, programs, and pipelines like Deramiocel and StealthX are available online and via its social media channels.